DERIVING A CUT-OFF FOR THE ELECSYS® β-AMYLOID (1–42) IMMUNOASSAY FOR USE IN CLINICAL TRIALS SUPPORTED BY ELI LILLY FOR PATIENTS WITH CLINICALLY DEFINED ALZHEIMER’S DISEASE (AD)
Alzheimers & Dementia（2017）
关键词
β‐amyloid,alzheimer,immunoassay,clinical trials,eli lilly
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要